Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Cationic peptide carriers enable long-term delivery of insulin-like growth factor-1 to suppress osteoarthritis-induced matrix degradation

Fig. 4

Experimental design to study biological effectiveness of CPC-IGF-1 using post-traumatic OA cartilage explant culture models. A Explants were treated with IL-1α (2 ng/ml) for the 16-day culture duration and received either (i) a single dose of 100 ng/ml (S) of free IGF-1, (ii) a continuous dose of 100 ng/ml (C) of free IGF-1, (iii) a single dose 1000 ng/ml (S) of free IGF-1, or (iv) a one-time dose of 1000 ng/ml (S) CPC-IGF-1 conjugate. (v) An untreated control, (vi) explants with single dose of CPC, and (vii) explants with IL-1α dosage only were also added as comparisons. B Percentage cumulative GAG loss to media over 16 days. C Cellular metabolism measured at days 8 and 16 using AlamarBlue assay. D Nitrite release determined by Griess assay at days 2, 8, and 16 (* vs control, # vs IL-1α, $ vs single dose 1000 ng/ml IGF-1 condition. In curve B, the statistical markers are color coordinated and all the data points enclosed within similar markers are statistically significant)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us